Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 12, 2026 16:05 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L...
August 06, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis Reports Financial Results for the Second Quarter 2026

Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01) FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first interim...
August 06, 2026 16:30 ET | Source: Cellectis Inc.

Cellectis publie ses résultats financiers du deuxième trimestre 2026

Lasmé-cel: phase 2 pivotale dans la LAL-B en rechute ou réfractaire (étude BALLI-01) Lasmé-cel a reçu le statut RMAT de la FDARésultats complets de phase 1 pour lasmé-cel présentés au congrès annuel...
August 06, 2026 16:05 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

PiNACLE pivotal clinical trial evaluating ronde-cel in 3L+ patients with LBCL on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected...
August 04, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...
July 29, 2026 08:30 ET | Source: Allogene Therapeutics, Inc.

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

FDA Granted RMAT Designation Based on ALPHA3 Trial Futility Analysis, Highlighting Cema-Cel’s Potential to Transform Disease Treatment in First-Line LBCL Consolidation Cema-Cel Induced Rapid and...
June 25, 2026 08:00 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen...
June 12, 2026 12:45 ET | Source: Lyell Immunopharma, Inc

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient...
June 11, 2026 02:40 ET | Source: Cellectis Inc.

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...
June 11, 2026 02:40 ET | Source: Cellectis Inc.

Cellectis présente les résultats finaux de phase 1 pour lasmé-cel et des résultats préliminaires pour éti-cel au congrès de l’EHA 2026

NEW YORK, 11 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour...